World's Best Scientists 2026 revealed!
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
134
Citations
90399
World Ranking
2109
National Ranking
23

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Rafael Rosell is affiliated with the Autonomous University of Barcelona in Spain. Their research primarily focuses on Medicine, with a concentration in Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging, and Cancer Research.

Key topics in their work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Cancer therapeutics and mechanisms
  • Lung Cancer Research Studies
  • Peptidase Inhibition and Analysis
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Genomics and Diagnostics

Among their recent publications are:

  • Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial, 2024, The Lancet Respiratory Medicine
  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer, 2020, UNC Libraries
  • 285 (PB273): RET overexpression in absence of fusions or mutations associates with sensitivity to RET TKIs in lung cancer, 2024, European Journal of Cancer
  • Cross-Method Comparison for Braf P.V600 Mutation Cfdna Testing in Melanoma: Brafi Study, 2025, SSRN Electronic Journal
  • Cross-Method Comparison for Braf P.V600 Mutation Cfdna Testing in Melanoma: Brafi Study, 2025, SSRN Electronic Journal

Frequent co-authors in their research collaborations include:

  • María González-Cao
  • Miguel Ángel Molina-Vila
  • Ana Drozdowskyj
  • Ruth Román
  • Clara Mayo de las Casas

Key venues where Rafael Rosell has published work include:

  • SSRN Electronic Journal
  • The Lancet Respiratory Medicine
  • UNC Libraries
  • European Journal of Cancer
  • Toxicology Letters

Best Publications

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    Rafael Rosell;Teresa Moran;Cristina Queralt;Rut Porta

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

    Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale

  • Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial

    Jean Yves Douillard;Rafael Rosell;Mario De Lena;Francesco Carpagnano

  • A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

    R Rosell;J Gómez-Codina;C Camps;J Maestre

  • Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

    Zhenfeng Zhang;Zhenfeng Zhang;Jae Cheol Lee;Luping Lin;Victor Olivas

  • Detection of Aberrant Promoter Hypermethylation of Tumor Suppressor Genes in Serum DNA from Non-Small Cell Lung Cancer Patients

    Manel Esteller;Montserrat Sanchez-Cespedes;Rafael Rosell;David Sidransky

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

    Yi-Long Wu;Ying Cheng;Xiangdong Zhou;Ki Hyeong Lee

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

    H. J. N. Andreyev;A. R. Norman;D. Cunningham;J. Oates

  • Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

    Reginald V N Lord;Jan Brabender;David R Gandara;Vicente Alberola

  • Non-small-cell lung cancer

    Cesare Gridelli;Antonio Rossi;David P Carbone;Juliana Guarize

  • Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Andrea Ardizzoni;Luca Boni;Marcello Tiseo;Frank V. Fossella

  • A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non–Small-Cell Lung Cancers

    Mariano Monzó;Rafael Rosell;Enriqueta Felip;Julio Astudillo

  • Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

    Manuel Cobo;Dolores Isla;Bartomeu Massuti;Ana Montes

  • Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

    Felipe Cardenal;M. Paz López-Cabrerizo;Antonio Antón;Vicente Alberola

Frequent Co-Authors

Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Mariano Provencio
Mariano Provencio Autonomous University of Madrid
Tony Mok
Tony Mok Chinese University of Hong Kong
Giorgio V. Scagliotti
Giorgio V. Scagliotti University of Turin
Jacek Jassem
Jacek Jassem Gdańsk Medical University
Alfredo Carrato
Alfredo Carrato University of Alcalá
Rolf A. Stahel
Rolf A. Stahel University of Zurich
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Alice T. Shaw
Alice T. Shaw Harvard University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in Medicine but want flexible or alternative options, there are several related online degrees and career pathways to explore. Programs like a bachelor of health information management online can prepare you for critical healthcare roles—without the need for traditional, on-campus study.

Another rapidly growing field is medical billing and coding. If you’re curious about the training, you may wonder how much does it cost to become a medical coder. Online programs offer affordable and flexible pathways into this in-demand profession.

For those aiming for advanced clinical roles, nurse practitioner programs are also widely available online. Students often seek the cheapest np school options to keep tuition affordable while boosting their career opportunities.

In nursing, there are many accredited and accessible pathways as well. Prospective registered nurses can research the cheapest online bsn programs to earn their degree from home, saving money and gaining flexibility in the process.

Best Scientists Citing Rafael Rosell

Trending Scientists

Recently Published Articles